In particular, in the patient with COVID-19 and HD the expressions of the CD38 and of the IFIT3 genes are strongly increased, while in the patient with COVID-19 and CLL they are both normally expressed at a level comparable to that observed in the COVID-19 patients without the Low T3 syndrome. This evidence concerns the gene CD38 and COVID-19.